Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
April 11, 2024 07:55 ET
|
Enliven Therapeutics, Inc.
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial...
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
April 09, 2024 16:05 ET
|
Enliven Therapeutics, Inc.
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
March 28, 2024 16:05 ET
|
Enliven Therapeutics, Inc.
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
March 19, 2024 08:30 ET
|
Enliven Therapeutics, Inc.
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026...
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 14, 2024 16:05 ET
|
Enliven Therapeutics, Inc.
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in...
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
February 27, 2024 16:05 ET
|
Enliven Therapeutics, Inc.
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation...
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023 16:05 ET
|
Enliven Therapeutics, Inc.
Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable...
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 10, 2023 16:05 ET
|
Enliven Therapeutics, Inc.
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024 Strong balance...
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
May 31, 2023 16:55 ET
|
Enliven Therapeutics, Inc.
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of...
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
May 11, 2023 16:05 ET
|
Enliven Therapeutics, Inc.
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell...